PDCD1 and urothelial carcinoma: Enfortumab vedotin, a mAb targeting nectin-4, has shown substantial efficacy to prolong survival for patients with advanced urothelial carcinoma who previously received chemotherapy and PD-1/PD-L1 inhibitors [162,163].